51656-90-7

Basic information

• Product Name: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE
• Synonyms: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE;1,4-Dioxaspiro[4.5]decane, 8-methylene-
• CAS NO: 51656-90-7
• Molecular Formula: C₉H₁₄O₂
• Molecular Weight: 154.21
• Product Categories: Miscellaneous
• Mol File: 51656-90-7.mol

Chemical Properties

• Boiling Point: 221.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE(51656-90-7)
• EPA Substance Registry System: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE(51656-90-7)

Safety Data

• Hazardous Substances Data: 51656-90-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE is used as a building block for the synthesis of various pharmaceutical compounds due to its unique spiro ring structure. Its versatile properties allow for the development of new drugs with improved efficacy and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE serves as a key component in the synthesis of various agrochemicals, such as pesticides and herbicides. Its unique structure contributes to the development of more effective and environmentally friendly products.
Used in Chemical Research and Development:
8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE is utilized in chemical research and development as a valuable compound for exploring new chemical reactions and synthesizing novel organic compounds. Its unique spiro ring structure provides opportunities for innovative approaches in chemical synthesis and the discovery of new chemical entities.
Used in Specialty Chemicals Production:
8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE is used as a key component in the production of specialty chemicals, which are high-value chemicals with specific applications in various industries. Its unique structure and properties make it an essential building block for the development of these specialty chemicals, enhancing their performance and functionality.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 19493-09-5 Methylenetriphenylphosphorane 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 4210-04-2 3,5-bis(trifluoromethyl)phenyl methyl sulfone 
• 873869-19-3 1-(tert-butyl)-5-(methylsulfonyl)-1H-tetrazole 
• 183-97-1 1,4,9,12-Tetraoxa-dispiro[4.2.4.2]tetradecane 
• 27200-84-6 methyl triphenylphosphonium bromide 
• 2065-66-9 methyl-triphenylphosphonium iodide 

Downstream Products

• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 93245-98-8 1,4-dioxaspiro[4.5]decane-8-carbaldehyde 
• 29648-66-6 4-methylenecyclohexanone 
• 15811-21-9 spiro[2.5]octan-6-one 
• 599174-26-2 4-(4-methoxy-benzyloxymethyl)-cyclohexylamine 
• 599174-25-1 4-(4-methoxy-benzyloxymethyl)-cyclohexanone 
• 599174-27-3 1-(4-isocyanato-cyclohexylmethoxymethyl)-4-methoxy-benzene 
• 599174-24-0 8-(4-methoxy-benzyloxymethyl)-1,4-dioxa-spiro[4.5]decane 
• 599174-28-4 C₃₂H₄₂N₄O₇S 
• 502870-59-9 1-(difluoromethylene)-4-methylenecyclohexane 
• 118537-40-9 4-<2-(4-Oxocyclohexyl)ethyl>benzoic Acid 
• 118537-39-6 Methyl 4-<2-(4-Oxocyclohexyl)ethyl>benzoate 
• 118537-49-8 tert-Butyl 4-<2-(4-Oxocyclohexyl)ethyl>benzoate 
• 118537-38-5 Methyl 4-<2-(1,4-Dioxaspiro<4.5>dec-8-yl)ethyl>benzoate 

Relevant articles and documents

Stereoselective Diboration of Spirocyclobutenes: A Platform for the Synthesis of Spirocycles with Orthogonal Exit Vectors

The diastereo- and enantioselective diboration of spirocyclobutenes provides a platform for the rapid preparation of a wide variety of chiral spirocyclic building blocks. The chemoselective functionalization of the carbon-boron bond in the products, including a stereospecific sp3-sp2 Suzuki–Miyaura cross-coupling reaction, provides a powerful tool to control the directionality and the nature of the exit vectors in the spirocyclic framework.

PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV

The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

PYRIDAZINONE DERIVATIVE

Provided are: a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or a prophylactic agent for diseases in which Nav1.1 is involved and various central nervous system diseases; and a medicine containing the pyridazinone derivative and/or the pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof. [In the formula, M1 represents a saturated or partially unsaturated C4-12 carbocyclic group or the like; R1 and R2 independently represent a hydrogen atom or the like; M2 represents a group represented by formula (2a) or the like; X1a, X1b and X1c independently represent N or the like; X2, X3 and X4 independently represent CR3 or the like; A1 and A2 independently represent N or the like; and R3 represents a hydrogen atom or the like.]

KINASE INHIBITORS

Disclosed herein are protein kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, pharmaceutical compositions comprising them, processes for preparing them and uses of such protein kinase inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function. In particular, the present invention relates to selective BTK inhibitors.

STAT DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR

Disclosed in the present invention are an indoleamine-2,3-dioxygenase inhibitor and a preparation method therefor. The inhibitor of the present invention has a structure as represented by general formula (I), wherein the definitions of Ar, E, Y, X, V, D, W, B, ring A and ring B are as shown in the description and claims. Also disclosed in the present invention is a preparation method for the inhibitor. The compound of general formula (I) of the present invention can be used as an indoleamine-2,3-dioxygenase inhibitor for preparing a medicament for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.

Rhodium-Catalyzed Intermolecular Cyclopropanation of Benzofurans, Indoles, and Alkenes via Cyclopropene Ring Opening

The generation of metal carbenoids via ring opening of cyclopropenes by transition metals offers a simple entry into highly reactive intermediates. Herein, we describe a diastereoselective intermolecular rhodium-catalyzed cyclopropanation of heterocycles and alkenes using cyclopropenes as carbene precursors with a low loading of a commercially available rhodium catalyst. The reported method is scalable and could be performed with catalyst loadings as low as 0.2 mol %, with no impact to the reaction yield or selectivity.

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

Provided are IDO1 inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).